In just one year, the healthcare supply chain leader achieves 80% YoY growth, ₹582 crore (including GMV) topline in Q2, and turns EBITDA positive through disciplined execution and strategic realignment.

One year ago, Medikabazaar embarked on a strategic path of hypergrowth with a clear focus on profitability. The roadmap was built on four strong pillars — strengthening its national presence, expanding its digital ecosystem, leveraging technology-led procurement solutions, and driving global expansion.

The company’s 450+ strong on-ground team, working closely with healthcare institutions across the country, has been instrumental in scaling its one-stop procurement platform. Alongside, 35+ exclusive tie-ups with leading OEMs and manufacturers have further enhanced product access and profitability.

Simultaneously, MB+, Medikabazaar’s in-house brand for medical consumables, devices, and equipment, with a targeted  ARR of ₹100 crore milestone by March 2026 establishing itself as one of the fastest-growing and most trusted healthcare brands in India. The brand is steadily positioning Indian-made medical products in global markets, making healthcare affordable and accessible across the country.

The company’s Digital Marketplace, with over 2 lakh SKUs across five major healthcare categories and attracting over 1 million visitors monthly, continues to demonstrate strong momentum, with a targeted  Annual Recurring Revenue (ARR) of ₹250 crore by March 2026

Adding further strength is Medika Business Solutions (MBS) a tech-driven, single-window procurement platform for hospitals that offers 5,000+ SKUs with complete transparency in pricing. This innovation has streamlined institutional procurement while ensuring efficiency and cost optimization by removing the middlemen.

Expanding beyond India, Medikabazaar has also established an international presence in the Middle East ( DUBAI) , China, and Africa, taking its mission of making healthcare available, accessible, and affordable to the global stage. Its partnership with AMTZ (Andhra Pradesh MedTech Zone) and the growing success of MB+ are set to further drive global healthcare collaborations and manufacturing synergies. With a focus on make in India

These strategic tracks ,combined with strong corporate governance, financial discipline, and process excellence — have enabled Medikabazaar to deliver a landmark performance. The company has stabilized operations, strengthened cash generation, and achieved an EBITDA-positive result for the first time. In the recently completed Q2, Medikabazaar recorded ₹582 crore(including GMV) in topline revenue, reflecting 80% year-on-year growth and underscoring the strength of its renewed strategy and execution.